Last reviewed · How we verify
Potassium Phosphates (Potassium Phosphate, Dibasic)
Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization.
Potassium phosphates injection is an inorganic phosphate replacement indicated for hypophosphatemia correction and parenteral nutrition in adults and pediatric patients. The drug is contraindicated in hyperkalemia, severe renal impairment, hyperphosphatemia, and abnormal calcium levels. Significant drug interactions exist with potassium-elevating agents requiring careful monitoring or avoidance. Renal function and serum electrolytes must be closely monitored during therapy.
At a glance
| Generic name | Potassium Phosphate, Dibasic |
|---|---|
| Sponsor | Pfizer |
| Drug class | Electrolyte replacement |
| Target | Phosphorus homeostasis and cellular biochemical functions |
| Modality | Small molecule |
| Therapeutic area | Nephrology |
| Phase | FDA-approved |
| First approval | 1993 |
Mechanism of action
Phosphorus in the form of inorganic phosphate has critical biochemical functions in all organs and tissues. These functions include roles in nucleic acid structure, energy storage and transfer, cell signaling, cell membrane composition and structure, acid-base balance, mineral homeostasis and bone mineralization. The drug provides exogenous phosphorus to correct deficiency states when oral or enteral replacement is not feasible.
Approved indications
- Treatment of potassium deficiency (hypokalemia) in patients with normal renal function.
- Treatment of potassium deficiency (hypokalemia) in patients with impaired renal function.
- Treatment of potassium deficiency (hypokalemia) in patients with potassium-wasting nephropathy.
- Treatment of potassium deficiency (hypokalemia) in patients with potassium-wasting renal tubular acidosis.
- Treatment of potassium deficiency (hypokalemia) in patients with potassium-wasting conditions.
- Treatment of potassium deficiency (hypokalemia) in patients with hyperaldosteronism.
- Treatment of potassium deficiency (hypokalemia) in patients with Cushing's syndrome.
- Treatment of potassium deficiency (hypokalemia) in patients with primary aldosteronism.
- Treatment of potassium deficiency (hypokalemia) in patients with hyperthyroidism.
- Treatment of potassium deficiency (hypokalemia) in patients with hyperparathyroidism.
- Treatment of potassium deficiency (hypokalemia) in patients with gastrointestinal disorders.
- Treatment of potassium deficiency (hypokalemia) in patients with diarrhea.
- Treatment of potassium deficiency (hypokalemia) in patients with vomiting.
- Treatment of potassium deficiency (hypokalemia) in patients with nasogastric suction.
- Treatment of potassium deficiency (hypokalemia) in patients with potassium loss due to medications.
- Treatment of potassium deficiency (hypokalemia) in patients with potassium loss due to other conditions.
- Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other conditions.
- Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to medications.
- Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other factors.
- Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other causes.
Common side effects
- Rash
- Febrile neutropenia
- Conjunctivitis
- Abdominal pain upper
- Diarrhoea
- Dyspepsia
- Nausea
- Oral pain
- Fungal skin infection
- Oral intake reduced
- Flank pain
- Anxiety
Drug interactions
- Potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, tacrolimus, cyclosporine
Key clinical trials
- Skin Barrier Function and Inflammation in Aging: The BIA Study (PHASE4)
- CReep and Maintenance flUid Sodium Chloride ADministration rEduction in cRitically Ill adultS (PHASE4)
- Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation (PHASE2)
- Hepatitis B Vaccine Delivered Trans-dermally by MAP (PHASE1)
- Benefits of Alcoholic Hangover Medicine (NA)
- Randomized Controlled Trial to Study the Outcome of Intravenous Phosphate Supplementation in Live Donors Undergoing Hepatectomy for Living Donor Liver Transplantation (LDLT) (PHASE4)
- Identifying the Brain Substrates of Hypoglycemia Unawareness in Type 1 Diabetes (EARLY_PHASE1)
- Anti-inflammatory Steroids in the Prevention of Tooth Sensitivity (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |